EMD Serono broke ground in May of 2016 on a $12 million expansion of its biopharmaceutical manufacturing campus in Billerica, Mass. Accommodating 120 employees, the two-story, 30,000-sf facility will support the development of advanced therapies for the treatment of cancer and immunological conditions. The project will be constructed as an extension of the existing Sagamore Building and will feature open-plan work areas, a central auditorium, and numerous meeting spaces, including bleacher seating for spontaneous collaboration and interaction. Completion is expected in June 2017.
In addition to seeking LEED certification to complement the Sagamore Building's Platinum LEED status, EMD Serono will also apply for the WELL Institute certification. The WELL Institute standard measures the human health and wellness of occupants in the building environment. If achieved, the facility will be one of the first projects in the United States to attain that certification.
EMD Serono is a subsidiary of German pharmaceutical firm Merck.
